jankie
Greenlighter
- Joined
- Dec 21, 2014
- Messages
- 19
I've heard that in a laboratory setting, this drug has been witnessed to cause re-wiring of damaged neural pathways, but due to lack of adequate research, it's impossible to get a prescription. I've also heard that it has cured social anxiety with just one 10-day treatment. Here's an abstract to one study. I have the full text if anyone is interested.
Does D-Cycloserine Enhance Exposure Therapy forAnxiety Disorders in Humans? A Meta-Analysis
Helga Rodrigues1*, Ivan Figueira1, Alessandra Lopes1, Raquel Gonc ̧alves1, Mauro Vitor Mendlowicz2,
Evandro Silva Freire Coutinho3, Paula Ventura4
The treatment of anxiety is on the edge of a new era of combinations of pharmacologic and psychosocial interventions. Anew wave of translational research has focused on the use of pharmacological agents as psychotherapy adjuvants usingneurobiological insights into the mechanism of the action of certain psychological treatments such as exposure therapy.Recently, d-cycloserine (DCS) an antibiotic used to treat tuberculosis has been applied to enhance exposure-basedtreatment for anxiety and has proved to be a promising, but as yet unproven intervention. The present study aimed toevaluate the efficacy of DCS in the enhancement of exposure therapy in anxiety disorders. A systematic review/meta-analysis was conducted. Electronic searches were conducted in the databases ISI-Web of Science, Pubmed and PsycINFO.We included only randomized, double-blind, placebo-controlled trials with humans, focusing on the role of DCS inenhancing the action of exposure therapy for anxiety disorders. We identified 328 references, 13 studies were included inour final sample: 4 on obsessive-compulsive disorder, 2 on panic disorder, 2 on social anxiety disorder, 2 on posttraumaticstress disorder, one on acrophobia, and 2 on snake phobia. The results of the present meta-analysis show that DCSenhances exposure therapy in the treatment of anxiety disorders (Cohen d = 20.34; CI: 20.54 to 20.14), facilitating thespecific process of extinction of fear. DCS seems to be effective when administered at a time close to the exposure therapy,at low doses and a limited number of times. DCS emerges as a potential new therapeutic approach for patients withrefractory anxiety disorders that are unresponsive to the conventional treatments available. When administered correctly,DCS is a promising strategy for augmentation of CBT and could reduce health care costs, drop-out rates and bring fasterrelief to patients.
From what I understand, it is a partial NMDA agonist...
Does D-Cycloserine Enhance Exposure Therapy forAnxiety Disorders in Humans? A Meta-Analysis
Helga Rodrigues1*, Ivan Figueira1, Alessandra Lopes1, Raquel Gonc ̧alves1, Mauro Vitor Mendlowicz2,
Evandro Silva Freire Coutinho3, Paula Ventura4
The treatment of anxiety is on the edge of a new era of combinations of pharmacologic and psychosocial interventions. Anew wave of translational research has focused on the use of pharmacological agents as psychotherapy adjuvants usingneurobiological insights into the mechanism of the action of certain psychological treatments such as exposure therapy.Recently, d-cycloserine (DCS) an antibiotic used to treat tuberculosis has been applied to enhance exposure-basedtreatment for anxiety and has proved to be a promising, but as yet unproven intervention. The present study aimed toevaluate the efficacy of DCS in the enhancement of exposure therapy in anxiety disorders. A systematic review/meta-analysis was conducted. Electronic searches were conducted in the databases ISI-Web of Science, Pubmed and PsycINFO.We included only randomized, double-blind, placebo-controlled trials with humans, focusing on the role of DCS inenhancing the action of exposure therapy for anxiety disorders. We identified 328 references, 13 studies were included inour final sample: 4 on obsessive-compulsive disorder, 2 on panic disorder, 2 on social anxiety disorder, 2 on posttraumaticstress disorder, one on acrophobia, and 2 on snake phobia. The results of the present meta-analysis show that DCSenhances exposure therapy in the treatment of anxiety disorders (Cohen d = 20.34; CI: 20.54 to 20.14), facilitating thespecific process of extinction of fear. DCS seems to be effective when administered at a time close to the exposure therapy,at low doses and a limited number of times. DCS emerges as a potential new therapeutic approach for patients withrefractory anxiety disorders that are unresponsive to the conventional treatments available. When administered correctly,DCS is a promising strategy for augmentation of CBT and could reduce health care costs, drop-out rates and bring fasterrelief to patients.
From what I understand, it is a partial NMDA agonist...